RVTY
Revvity, Inc.
NYSE · Healthcare · Medical - Diagnostics & Research · US
$130.22
−0.31%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.9B | 2.9B | 2.8B | 2.8B | 3.3B |
| Cost of Revenue | 1.4B | 1.3B | 1.4B | 1.4B | 1.6B |
| Gross Profit | 1.5B | 1.5B | 1.3B | 1.3B | 1.8B |
| Operating Expenses | |||||
| R&D Expense | 215.8M | 215.8M | 196.8M | 216.6M | 221.6M |
| SG&A Expense | 942.6M | 945.3M | 715.3M | 706.1M | 758.0M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | (1.7M) | — | — | — |
| Total Operating Expenses | 1.2B | 1.2B | 912.1M | 922.7M | 979.6M |
| Cost and Expenses | 2.6B | 2.5B | 2.3B | 2.4B | 2.5B |
| Operating Income (EBIT) | 358.8M | 356.6M | 410.5M | 399.5M | 781.1M |
| Non-Operating | |||||
| Interest Income | 24.2M | 31.1M | 73.2M | 72.1M | 3.6M |
| Interest Expense | 94.0M | 92.2M | 96.3M | 98.8M | 104.0M |
| Net Interest Income | (69.8M) | (61.1M) | (23.1M) | (26.7M) | (100.4M) |
| Other Non-Op Income/Expense | (98.1M) | (88.4M) | (94.4M) | (216.5M) | (129.3M) |
| Non-Operating Income (excl Interest) | 4.1M | (3.8M) | (1.9M) | 117.7M | 25.3M |
| EBT (Pre-Tax Income) | 260.8M | 268.3M | 316.1M | 183.0M | 651.8M |
| Income Tax Expense | 20.8M | 25.8M | 33.1M | 3.5M | 139.2M |
| Bottom Line | |||||
| Net Income | 237.6M | 241.7M | 295.8M | (118.4M) | 569.2M |
| Earnings from Cont. Ops | 240.0M | 242.5M | 283.1M | 179.5M | 512.7M |
| Earnings from Discont. Ops | (2.4M) | (975.0K) | 12.8M | (297.9M) | 56.5M |
| Bottom Line Net Income | 237.6M | 241.7M | 295.8M | (118.4M) | 569.2M |
| Per Share | |||||
| Basic EPS | $2.10 | $2.08 | $2.41 | ($0.95) | $4.51 |
| Diluted EPS | $2.10 | $2.08 | $2.41 | ($0.95) | $4.50 |
| Revenue Per Share | $26.06 | $25.23 | $22.44 | $22.06 | $26.25 |
| Shares | |||||
| Basic Shares Outstanding | 111.7M | 113.2M | 122.8M | 124.7M | 126.2M |
| Diluted Shares Outstanding | 111.7M | 113.2M | 122.8M | 124.8M | 126.4M |
| Profitability Metrics | |||||
| EBITDA | 767.0M | 662.7M | 840.3M | 713.6M | 1.2B |
| D&A | 412.2M | 302.3M | 427.8M | 431.8M | 427.0M |
| EBIT | 354.8M | 360.5M | 412.4M | 281.8M | 755.8M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jul 1, 2026